This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

ZAVICEFTA® (ceftazidime-avibactam): Broad-spectrum Gram-negative coverage with consistent dosing across indications1–4

ZAVICEFTA (ceftazidime-avibactam) has consistent dosing across indications1.

No dose adjustments required in the elderly, patients with mild renal impairment (estimated CrCl >50 to ≤80 mL/min) and those with hepatic impairment1

Table 1. Recommended dose for adult patients with estimated CrCL* > 50mL/min1

Recommended dose for adult patients with estimated CrCL* > 50mL/min

Table 1 footnotes:
§ The total duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.
║There is very limited experience with the use of ZAVICEFTA for more than 14 days.
* The dose of ZAVICEFTA in patients with estimated CrCL ≤50 mL/min should be adjusted according to recommended doses. CrCL estimated using the Cockcroft-Gault formula.
† To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.
‡ To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.

No dosage adjustment is required in:

  • The elderly
  • Patients with mild renal impairment (estimated CrCL from >50 to ≤80 mL/min)
  • Patients with hepatic impairment

Table 2. Recommended dose adjustments in adult patients with estimated CrCL* ≤ 50 mL/min1

Recommended dose adjustments in adult patients with estimated CrCL1 ≤ 50 mL/min

Table 2 footnotes:
* CrCL estimated using the Cockcroft-Gault formula.
† Dose recommendations are based on pharmacokinetic modelling.
​​​​​​​‡ Ceftazidime and avibactam are removed by haemodialysis. Dosing of ZAVICEFTA on haemodialysis days should occur after completion of haemodialysis

​​​​​​​

Table 3. Recommended dose for paediatric patients1 with estimated CrCL* > 50 mL/min/1.73 m2

Recommended dose for paediatric patients with estimated CrCL1 > 50 mL/min/1.73 m2

When treating for cIAI, cUTI, HAP/VAP or LTO to be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process. 
When treating for cIAI or LTO, to be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.

Table 3 footnotes:
*  CrCL estimated using the Schwartz bedside formula.
¶ The total treatment duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.
ǁ There is very limited experience with the use of ZAVICEFTA for more than 14 days.
​​​​​​​**There is limited experience with the use of ZAVICEFTA in paediatric patients 3 months to < 6 month.​​​​​​​

​​​​​​​Table 4. Recommended dose for paediatric patients1 with estimated CrCL* ≤ 50 mL/min/1.73 m2

​​​​​​​Recommended dose for paediatric patients with estimated CrCL1 ≤ 50 mL/min/1.73 m2​​​​​​​

Table 4 footnotes:
*CrCL estimated using the Schwartz beside formula
† Dose recommendations are based on pharmacokinetic modelling
**Ceftazidime and avibactam are removed by haemodialysis. Dosing of ZAVICEFTA on haemodialysis days should occur after completion of haemodialysis. 
​​​​​​​


Table 5. Recommended dose for paediatric patients ≥ 3 months and < 2 years of age1 with estimated CrCL* ≤ 50 mL/min/1.73 m2

​​​​​​Recommended dose for paediatric patients ≥ 3 months and < 2 years of age with estimated CrCL1 ≤ 50 mL/min/1.73 m2

Table 5 footnotes:
​​​​​​​*CrCL estimated using the Schwartz bedside formula
†Dose recommendations are based on pharmacokinetic modelling

There is insufficient information to recommend a dosage regimen for paediatric patients < 2 years of age that have a CrCL < 16 mL/min/1.73m2
​​​​​​​

Explore more​​​​​​​

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

Access case studies and videos


Abbreviations

cIAI, complicated intra-abdominal infection; CrCL, creatinine clearance; cUTI, complicated urinary tract infection; ESRD, end stage renal disease; HAP, hospital-acquired pneumonia; LTO, limited treatment options; VAP, ventilator-associated pneumonia; ELF, epithelial lining fluid; AMR, Antimicrobial Resistance; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing.

References
  1. ZAVICEFTA. Summary of Product Characteristics
  2. Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–7
  3. Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9
  4. ​​​​​​​Mazuski JE, et al. Surg Infect 2017;18:1–76
PP-ZVA-GBR-0845. June 2021

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View safety profile

Quick Links

  • Patient Risk Factors

  • Pathogen Coverage

  • AMS Resources

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No